More recently, other NO-generating agents, such as the diazeniumdiolate pro-NO drugs that are activated by GSH via GSTs, have been studied in terms of developing novel anti-cancer drugs [59,60,61,62,63,64,65]. The gene discussed is HPGDS; the disease is cancer.